In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing.

This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials.

Listeners can expect:
1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab.
2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s.
3. ❌🤔 - Clarification of misconceptions about dementia therapies.
4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice.
5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies.

#Lecanemab #Donanemab #Dementia #alzheimerdisease #genetics #ucl #dementiatreatment

NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial:
https://www.nia.nih.gov/news/nia-stat...

NIA statement on donanemab results: More Alzheimer’s research progress:
https://www.nia.nih.gov/news/nia-stat...

Alzheimer's Society Information on Donanemab:
https://www.alzheimers.org.uk/blog/wh...

Alzheimer's Society Information on Lebanemab:
https://www.alzheimers.org.uk/blog/le...

Alzheimer's Association Info on Research & Risks
https://bit.ly/3QxH3Ei

Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk

Like what you see? Please comment, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to listen rather than watch, you’ll find a video version of this podcast with full captions on our YouTube Channel.

https://bit.ly/3QzCcSK

This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

00:00 Introductions
03:47 Understanding Amyloid and how it was discovered
10:42 What do the new Lecanemab and Donanemab treatments do?
16:49 Do treatments impact in Tau?
18:00 What's the state of play with current trials of these treatments?
22:56 What are the benefits of these new treatments?
26:06 Are there side-effects / downsides to the treatments?
30:56 How can people get involved in these trials?
35:46 When will these treatments be available in the UK?
38:51 What are the barriers to implementation?
44:18 Gene silencing therapy in Alzheimer’s disease
48:28 Challenges for the future
53:07 Roundup and Goodbyes

Follow us on Social Media:
  / dem_researcher  
  / dementia_researcher  
  / dementia.researcher